Immunotherapy is currently effective in less than half of patients with solid tumors, and most responders develop secondary progression. High infiltration of the tumor microenvironment (TME) with CD8 ...
1Graduate Program in Immunology and Microbiology, Baylor College of Medicine, Houston, Texas. 2Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital, and Houston ...
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States ...
1 Reproductive Center of Integrated Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China 2 Binzhou Hospital of Traditional Chinese Medicine, BinZhou, ...
METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial progression in patients receiving TTFields therapy and best supportive care following ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results